Standard BioTools Sells Microfluidics Business to ARCHIMED

Standard BioTools (LAB) has agreed to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The deal is expected to close in about 30 days and requires customary closing conditions. This strategic move allows Standard BioTools to focus on other core areas of the company while leveraging ARCHIMED's expertise in the healthcare sector.

By Harsh Shukla, SA News Editor · Seeking Alpha · October 5, 2026, 20:15 UTC

Standard BioTools Sells Microfluidics Business to ARCHIMED

Tickers: $LAB

Topics: Biotechnology M&A

Read the full article at Seeking Alpha

More World news

Spout Finance Integrates Ondo Stocks to Enable Interest-Free USDC Borrowing via Covered Calls PR Newswire · November 12, 2026, 14:30 UTC
Deswell Industries Announces Semi-Annual Dividend of $0.10 Per Share Seeking Alpha · November 12, 2026, 14:24 UTC
Nvidia Shares Plunge Following Announcement of CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 14:24 UTC
Archer Aviation Enters Multi-Year Partnership with Formula One Seeking Alpha · November 12, 2026, 14:16 UTC
Edgewell Personal Care Announces Quarterly Dividend of $0.15 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Hudbay Minerals Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Warby Parker Unveils AI-Powered Intelligent Eyewear Collection in Partnership with Google and Samsung Seeking Alpha · November 12, 2026, 14:17 UTC
Where Food Comes From Reports Q3 Revenue Growth and Improved Gross Margins Seeking Alpha · November 12, 2026, 14:17 UTC
Medical Care Technologies Inc. Reports Q3 Revenue Growth and Significant Net Income Increase Seeking Alpha · November 12, 2026, 14:17 UTC
Digi International Reports Record Fiscal 2026 Results and Announces Acquisition of Disruptive Technologies Motley Fool · November 12, 2026, 14:15 UTC